Chukwudi Amaechi Ofodile

Dr. Chukwudi Amaechi Ofodile

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2021 in Epidemiology and Health
Verified
Journal Article
Open access
PDF file
JOJude Okoye
Jude Okoye
COChukwudi Amaechi Ofodile
Chukwudi Amaechi Ofodile
OAOluwaseun Kelechi Adeleke
Oluwaseun Kelechi Adeleke
OOOkechi Obioma
Okechi Obioma
OBJECTIVES: This review assessed the rate of high-risk human papillomavirus (HPV) infection among women living in sub-Saharan Africa. It also determined the prevalence of high-risk HPV (hrHPV) among human immunodeficiency virus (HIV) seropositive (HIV+) and seronegative (HIV-) women in sub-Saharan Africa, pre-2010 and post-2010.METHODS: In this systematic review, Google Scholar, PubMed Central, and Embase were searched to identify cohort and case-control studies that investigated the relationship between HIV and HPV infection. The database searches yielded 17 studies published between 1999 and 2018.RESULTS: In the general population, the prevalence of any HPV/multiple HPV infections was higher among HIV+ (53.6/22.6%) than among HIV- women (26.5/7.3%) with odds ratios of 3.22 and 3.71, respectively (95% confidence interval, 3.00 to 3.42 and 2.39 to 5.75, p< 0.001). The prevalent HPV genotypes among HIV+ and HIV- women diagnosed with invasive cervical cancer (ICC) were HPV-16/18 and HPV-45. The prevalence of HPV-16, HPV-18, and HPV-45 was lower in 1999-2010 (3.8, 1.7, and 0.8%, respectively) than in 2011-2018 (19.1, 6.0, and 3.6%, respectively). Among women diagnosed with ICC, HIV+ women had a higher prevalence of HPV-56, HPV-31, and HPV-51 (7.3, 5.3, and 3.3%, respectively) than HIV- women (1.3, 2.2, and 0.4%, p< 0.001, p= 0.050, and p= 0.013, respectively).CONCLUSIONS: The prevalence of HPV infection, multiple HPV infections, and non-vaccine HPV types were higher among HIV+ women than among HIV- women in sub-Saharan Africa. Although HIV infection influences the distribution of HPV types, this study suggests that cervical cancer incidence in sub-Saharan Africa is primarily driven by the prevalence of vaccine hrHPVs, especially HPV-16 and HPV-18.

16 January 2025 in Viruses
Verified
Journal Article
Open access
PDF file
COChukwudi Amaechi Ofodile
Chukwudi Amaechi Ofodile
Ikemefuna UzochukwuIkemefuna Uzochukwu
Ikemefuna Uzochukwu
FEFortunatus Ezebuo
Fortunatus Ezebuo
IEInnocentMary IfedibaluChukwu Ejiofor
InnocentMary IfedibaluChukwu Ejiofor
MAMercy Adeola Adebola
Mercy Adeola Adebola
Juan De La TorreJuan De La Torre
Juan De La Torre
Lassa fever (LF), a viral hemorrhagic fever disease with a case fatality rate that can be over 20% among hospitalized LF patients, is endemic to many West African countries. Currently, no vaccines or therapies are specifically licensed to prevent or treat LF, hence the significance of developing therapeutics against the mammarenavirus Lassa virus (LASV), the causative agent of LF. We used in silico docking approaches to investigate the binding affinities of 2015 existing drugs to LASV proteins known to play critical roles in the formation and activity of the virus ribonucleoprotein complex (vRNP) responsible for directing replication and transcription of the viral genome. Validation of docking protocols were achieved with reference inhibitors of the respective targets. Our in silico docking screen identified five drugs (dexamethasone, tadalafil, mefloquine, ergocalciferol, and flunarizine) with strong predicted binding affinity to LASV proteins involved in the formation of the vRNP. We used cell-based functional assays to evaluate the antiviral activity of the five selected drugs. We found that flunarizine, a calcium-entry blocker, inhibited the vRNP activity of LASV and LCMV and virus surface glycoprotein fusion activity required for mammarenavirus cell entry. Consistently with these findings, flunarizine significantly reduced peak titers of LCMV in a multi-step growth kinetics assay in human A549 cells. Flunarizine is being used in several countries worldwide to treat vertigo and migraine, supporting the interest in exploring its repurposing as a candidate drug to treat LASV infections.

30 December 2024 in African Journal of Clinical and Experimental Microbiology
Verified
Journal Article
Open access
PDF file
COChetachi Blessing Okwuanaso
Chetachi Blessing Okwuanaso
NON. F. Onyemelukwe
N. F. Onyemelukwe
COChukwudi Amaechi Ofodile
Chukwudi Amaechi Ofodile
Background: There is a public health concern about carriage of Enterobacterales among food workers and their potential role for transmission of food-borne illnesses. Food contamination by Enterobacterales could happen at any point of the production, processing, distribution, and preparation processes. This challenge is especially severe in developing countries like Nigeria. The objective of this study is to determine the prevalence and pattern of carriage of Enterobacterales by food handlers in Nnewi metropolis, southeast Nigeria.Methodology: This was a cross-sectional study that employed a non-probability sampling technique to recruit 178 food handlers who gave their consent and were available at the sampling area during the time of the study. Stool, urine, nasal and hand swab samples were collected from 115, 116, 120 and 173 food handlers respectively for microbiological analysis using conventional culture isolation and biochemical identification by Analytical Profile Index (API) 20E (bioMérieux). The antimicrobial susceptibility testing of the isolates was carried out on the identified isolates by the disk diffusion method. Descriptive statistics were carried out on the data.Results: Forty-four (25.4%) of the hand swab samples from 173 food handlers, 39 (32.5%) of the nasal swabs from 120 food handlers, 67 (58.3%) of the stool samples from 115 food handlers, and 29 (25.0%) of the urine samples from 116 food handlers, were positive for Enterobacterales isolates. The frequency of Enterobacterales isolation was significantly higher from stool samples compared to other samples (x2=40.032; p<0.0001), indicating a higher carriage rate in the gastrointestinal tracts of the food handlers. Across all the samples, a total of 179 Enterobacterales were isolated from the 101 (56.7%) positive food handlers. The frequency of isolation in descending order is Escherichia coli 23.2% (n=41), Klebsiella spp 18.1% (n=32), Enterobacter spp 15.3% (n=27), Citrobacter spp 10.7% (n=19), Raoultella spp 7.3% (n=13), Serratia spp 5.6% (n=10), Salmonella spp 3.9% (n=7), Kluyvera spp 3.9% (n=7), Shigella spp 2.8% (n=5), Proteus spp 2.8% (n=5), Cronobacter spp 1.7% (n=3), Erwinia spp 1.1% (n=2), Pantoea spp 1.1% (n=2), Hafnia spp 1.1% (n=2), and Yersinia spp 1.1% (n=2). The Enterobacterales isolates were resistant to cefotaxime (83.0%), amoxicillin-clavulanic acid (79.1%), cefuroxime (76.8%), cefixime (75.1%), imipenem-cilastatin (74.6%), ceftazidime-avibactam (73.3%), ceftriaxone-sulbactam (71.2%) and levofloxacin (70.5%).Conclusion: Food handlers in this study had a high carriage rate of resistant Enterobacterales pathogens, which can be transmitted to unsuspecting consumers, through the food processing and handling chains.

14 November 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
COChukwudi Amaechi Ofodile
Chukwudi Amaechi Ofodile
Ikemefuna UzochukwuIkemefuna Uzochukwu
Ikemefuna Uzochukwu
FEFortunatus Ezebuo
Fortunatus Ezebuo
IEInnocentMary IfedibaluChukwu Ejiofor
InnocentMary IfedibaluChukwu Ejiofor
MAMercy Adeola Adebola
Mercy Adeola Adebola
Juan De La TorreJuan De La Torre
Juan De La Torre
Lassa fever (LF), a viral hemorrhagic fever disease with a case fatality rate that can be over 20% among hospitalized LF patients, is endemic to many West African countries. Currently, no vaccines or therapies are specifically licensed to prevent or treat LF. Hence, the significance of developing therapeutics against the mammarenavirus Lassa virus (LASV), the causative agent of LF. We used in silico docking approaches to investigate the binding affinities of 2015 existing drugs to LASV proteins known to play critical roles in the formation and activity of the virus ribonucleoprotein complex (vRNP) responsible for directing replication and transcription of the viral genome. Validation of docking protocols were achieved with reference inhibitors of the respective targets. Our in silico docking screen identified five drugs (dexamethasone, tadalafil, mefloquine, ergocalciferol, and flunarizine) with strong predicted binding affinity to LASV proteins involved in the formation of the vRNP. We used cell-based functional assays to evaluate the antiviral activity of the five selected drugs. We found that flunarizine, a calcium-entry blocker, inhibited the vRNP activity of LASV and LCMV, and virus surface glycoprotein fusion activity required for mammarenavirus cell entry. Consistent with these findings, flunarizine significantly reduced peak titers of LCMV in a multi-step growth kinetics assay in human A549 cells. Flunarizine is being used in several countries worldwide to treat vertigo and migraine, supporting the interest in exploring its repurposing as a candidate drug to treat LASV infections.

12 January 2026 in Viruses
Verified
Journal Article
Open access
PDF file
COChukwudi Amaechi Ofodile
Chukwudi Amaechi Ofodile
BIBeatrice Cubitt IMM-6
Beatrice Cubitt IMM-6
NONgozi Onyemelukwe
Ngozi Onyemelukwe
COChetachi Blessing Okwuanaso
Chetachi Blessing Okwuanaso
HWHaydar Jawad Kathim Witwit
Haydar Jawad Kathim Witwit
Juan De La TorreJuan De La Torre
Juan De La Torre
Mammarenaviruses (MaAv) cause persistent infection in their natural rodent hosts across the world and, via zoonotic events, can cause severe disease in humans. Thus, the MaAv Lassa virus (LASV) in Western Africa and the Junin virus (JUNV) in the Argentinean Pampas cause hemorrhagic fever diseases with significant case fatality rates in their endemic regions. In addition, the globally distributed MaAv lymphocytic choriomeningitis virus (LCMV) is an underrecognized human pathogen of clinical significance capable of causing devastating infections in neonates and immunocompromised individuals. Despite their impact on human health, there are currently no FDA-approved vaccines or specific antiviral treatments for MaAv infections. Existing anti-MaAv therapies are limited to the off-label use of ribavirin, whose efficacy remains controversial; hence, the development of novel therapeutics to combat human pathogenic MaAv is vital. We employed a high-throughput cell-based infection assay to screen the Pandemic Response Box, a collection of 400 diverse compounds with established antimicrobial activity, for MaAv inhibitors. We identified Ro-24-7429, an antagonist of the HIV-1 Tat protein and RUNX family transcription factor 1 inhibitor; WO 2006118607 A2, a dihydroorotate dehydrogenase inhibitor; and verdinexor, a novel selective inhibitor of nuclear export (SINE) targeting the XPO1/CRM1, as potent anti-MaAv compounds. Consistent with their distinct validated targets, verdinexor and WO 2006118607 A2 exhibited very strong synergistic antiviral activity when used in combination therapy. Our findings pave the way for the development of verdinexor as a potent host-directed antiviral against MaAv, which could be integrated into the development of combination therapy with direct- or host-acting antivirals to combat human pathogenic MaAv.

17 March 2026 in Jordan Medical Journal
Verified
Journal Article
Closed access
SESeyi Samson Enitan
Seyi Samson Enitan
RARichard Akele
Richard Akele
OOOsareniro Osakue
Osareniro Osakue
COChukwudi Amaechi Ofodile
Chukwudi Amaechi Ofodile
CIChinwendu Ikonne
Chinwendu Ikonne
OAOluwanifemi Ajayi
Oluwanifemi Ajayi
Type 1 Diabetes Mellitus (T1DM) is an autoimmune disorder characterized by the progressive destruction of pancreatic beta cells. Coxsackie B Virus (CVB), particularly CVB1, CVB3, and CVB4, has been identified as a key environmental trigger in the pathogenesis of T1DM, particularly in genetically predisposed individuals. This narrative review synthesizes two decades of evidence (2005–2025) to explore the mechanisms by which CVB contributes to autoimmunity and emerging prevention strategies. CVB induces beta cell autoimmunity through molecular mimicry, bystander activation, and persistent viral infections that promote chronic inflammation and immune-mediated beta cell damage. Specific serotypes, such as CVB3 and CVB4, have been shown to have stronger associations with T1DM onset, emphasizing the importance of targeted interventions for these serotypes. Recent advancements in prevention strategies include multivalent CVB vaccines, antiviral agents such as pleconaril, and immune-modulating therapies like tolerogenic vaccines and regulatory T cell (Treg) expansion. However, challenges remain regarding their safety, timing of administration, and immune cross-reactivity. Early diagnostic efforts focused on biomarkers such as CVB-specific antibodies, islet autoantibodies (e.g., GAD65, ICA, ZnT8), and HLA risk alleles are crucial for identifying individuals in the latent phase of T1DM. To mitigate the risk of CVB-induced T1DM, an integrated public health approach—combining virological surveillance, vaccination campaigns, and early immunological screening—is essential. We recommend prioritizing longitudinal cohort studies, the development of safe multivalent vaccines, and investment in community-based early detection programs. A collaborative, multidisciplinary approach is vital to prevent or delay T1DM onset in at-risk populations